Fiche publication
Date publication
janvier 2021
Journal
Infectious diseases now
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BONNIAUD Philippe
,
Dr BELTRAMO Guillaume
Tous les auteurs :
Ahouansou N, Georges M, Beltramo G, Aswad N, Hassani Y, Bonniaud P
Lien Pubmed
Résumé
Daptomycin is a widely used antibiotic. Rhabdomyolysis related to daptomycin is one of the adverse effects of treatment, justifying the need for regular monitoring of muscle enzymes throughout treatment. Daptomycin may also lead to eosinophilic pneumonia. However, risk factors for this adverse reaction have not been identified and do not permit targeting of at-risk populations who could benefit from appropriate monitoring.
Mots clés
Daptomycin, Pulmonary eosinophilia, Risk factor
Référence
Infect Dis Now. 2021 Jan 9;:
